Mirum Pharmaceuticals, Inc.
$96.13+$0.62 (+0.6%)
Last close · Data as of Nov 20, 2026
- Market cap
- $5.6B
- P/E
- -241.4x
- EV / EBITDA
- 329.1x
- Revenue
- $521.3M
- Net margin
- -4.5%
- ROCE
- -3.5%
Price chart
Technical chartScreen technicals →+39.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +13.0%
- 3M
- -1.0%
- 6M
- -0.8%
- 1Y
- +39.0%
- 5Y
- +512.7%
52-week range
Day change +$0.62 (+0.6%) from $96 to $96 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in MIRM, bought on each weekday since 2021.
News & filings
What Mirum Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 23.4 million US dollars in fiscal 2025.
Strengths (1)
- Revenue grew 54.7% in fiscal 2025.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Read moreShow less
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
- Sector
- Healthcare
- Shares outstanding
- 51.9M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $5.6B
- P/E
- -241.4x
- P/B
- 17.9x
- EV / EBITDA
- 329.1x
- EV / Sales
- 10.9x
- P/S
- 10.8x
- 52-week high
- $128.57
- 52-week low
- $64.10
Profitability
- Operating margin
- -4.2%
- Net margin
- -4.5%
- EBITDA margin
- 3.3%
- ROE
- -7.4%
- ROCE
- -3.5%
- ROIC
- -1.6%
- ROA
- -2.8%
- Asset turnover
- 0.62
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $521.3M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 54.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 89.1%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -73.4%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $54.9M
Solvency
- Current ratio
- 2.67
- Debt / Equity
- 1.02
- Debt / Assets
- 0.38
- CFO / Net profit
- -2.39
- Cash / Market cap
- 5.3%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $521.3M |
| Cost of revenue | $100.2M |
| Gross profit | $421.1M |
| Operating expenses | $443.2M |
| Research and development | $186.2M |
| Selling, general and administrative | $257.0M |
| Operating income | -$22.1M |
| Interest and other | $710.0k |
| Pretax income | -$21.4M |
| Tax and other | $1.9M |
| Net income | -$23.4M |
Revenue and net profit
Revenue grew 54.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $77.1M | -$135.7M |
| FY2023 | $186.4M | -$163.4M |
| FY2024 | $336.9M | -$87.9M |
| FY2025 | $521.3M | -$23.4M |
Cash flows
FY2025: $55.8M from operations, $54.9M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$120.1M | -$120.4M |
| FY2023 | -$70.9M | -$91.1M |
| FY2024 | $10.3M | -$10.7M |
| FY2025 | $55.8M | $54.9M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $521.3M+54.7%1Y
- EBITDA
- $17.2M
- Net profit
- -$23.4M
- Cash from operations
- $55.8M+440.7%1Y
- Free cash flow
- $54.9M
- Revenue CAGR, 3Y
- 89.1%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $521.3M | $17.2M | -$23.4M | $54.9M | -7.4% | +54.7% | -73.4% |
Monthly returns
Month-by-month returns of MIRM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $842.8M |
| Current assets | $549.7M |
| Non-current assets | $293.1M |
| Liabilities | $528.1M |
| Current liabilities | $205.8M |
| Non-current liabilities | $322.3M |
| Equity | $314.7M |
| Paid-in capital | $981.9M |
| Retained earnings | -$667.5M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; MIRM highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Terns Pharmaceuticals, Inc., Cogent Biosciences, Inc., CRISPR Therapeutics AG, Scholar Rock Holding Corporation.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc.MIRMthis company | $5.6B | -241.4x | 17.9x | -7.4% | 329.1x |
| Kymera Therapeutics, Inc.KYMR | $6.1B | — | 3.9x | -19.7% | — |
| Terns Pharmaceuticals, Inc.TERN | $6.1B | -63.6x | 6.1x | -9.6% | -51.0x |
| Rhythm Pharmaceuticals, Inc.RYTM | $6.0B | — | 22.3x | -74.8% | — |
| PACS Group, Inc.PACS | $5.9B | 31.0x | 6.3x | 20.2% | 25.0x |
| Cogent Biosciences, Inc.COGT | $5.6B | -17.0x | 10.2x | -60.1% | -17.2x |
| Liquidia CorporationLQDA | $5.6B | -80.7x | 124.3x | -154.0% | -128.8x |
| CRISPR Therapeutics AGCRSP | $5.5B | — | 2.9x | -30.3% | — |
| Scholar Rock Holding CorporationSRRK | $5.4B | — | 22.1x | -154.0% | — |
| Peer median | — | -40.3x | 8.3x | -45.2% | -34.1x |
Year-to-date ROI
MIRM since 1 January, against earlier years.
Historical volatility
MIRM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -170.3% |
| FY2023 | -58.6% |
| FY2024 | -26.0% |
| FY2025 | -4.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $521.3M |
| Cost of revenueCost Of Revenue | $100.2M |
| Gross profitGross Profit | $421.1M |
| Operating expensesOperating Expense | $443.2M |
| Research and developmentResearch And Development | $186.2M |
| Selling, general and administrativeSelling General And Administration | $257.0M |
| Total expensesTotal Expenses | $543.5M |
| Operating incomeOperating Income | -$22.1M |
| Interest and other | |
| Pretax incomePretax Income | -$21.4M |
| TaxTax Provision | $1.9M |
| Net incomeNet Income | -$23.4M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $842.8M |
| Current assetsCurrent Assets | $549.7M |
| Non-current assetsTotal Non Current Assets | $293.1M |
| LiabilitiesTotal Liabilities Net Minority Interest | $528.1M |
| Current liabilitiesCurrent Liabilities | $205.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $322.3M |
| EquityTotal Equity Gross Minority Interest | $314.7M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $55.8M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $55.8M |
| Net income, continuing operationsNet Income From Continuing Operations | -$23.4M |
| Depreciation and amortisationDepreciation And Amortization | $24.2M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $24.2M |
| Depreciation | — |
| Amortization of securitiesAmortization Of Securities | — |
| Stock-based compensationStock Based Compensation | $71.4M |
| Deferred taxDeferred Tax | — |
| Deferred income taxDeferred Income Tax | — |
| Operating gains and lossesOperating Gains Losses | -$1.7M |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | -$1.7M |
| Provision and write off of assetsProvisionand Write Offof Assets | $2.9M |
| Change in working capitalChange In Working Capital | -$19.7M |
| Other non-cash itemsOther Non Cash Items | $2.1M |
| Investing cash flowInvesting Cash Flow | -$23.9M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$23.9M |
| Capital expenditureCapital Expenditure | -$950.0k |
| Purchase of PP&EPurchase Of PPE | -$950.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$950.0k |
| AcquisitionsPurchase Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | -$97.4M |
| Sale of investmentsSale Of Investment | $74.4M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$23.0M |
| Purchase of intangiblesPurchase Of Intangibles | $0.00 |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | $0.00 |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | $40.1M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $40.1M |
| Debt issuedIssuance Of Debt | $0.00 |
| Net debt issuedNet Issuance Payments Of Debt | $0.00 |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Net long-term debt issuedNet Long Term Debt Issuance | $0.00 |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Common stock issuedCommon Stock Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $40.1M |
| Dividends paidCash Dividends Paid | — |
| Other financing chargesNet Other Financing Charges | — |
| Interest paid (financing)Interest Paid Cff | — |
| Change in cashChanges In Cash | $72.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 322.0% |
| Cash at the start of the yearBeginning Cash Position | $222.9M |
| Cash at the end of the yearEnd Cash Position | $298.2M |
| Free cash flowFree Cash Flow | $54.9M |
| Supplemental |
Learn while you research
Academy chapters picked for Mirum Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing55% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read